Presented at ASCO 2020
James M. Cleary1, Gopa Iyer2, Do-Youn Oh3, Ingo K. Mellinghoff2, Lipika Goyal4, Matthew CH Ng5, Funda Meric-Bernstam6, Ignacio Matos7, Tsu-Yi Chao8, Rafik Ait Sarkouh9, Kira Cretegny9, Yassin Marzaoui9, Valerie Nicolas-Metral9, Anna Pokorska-Bocci9, Marie-Claude Roubaudi-Fraschini9, Anne Vaslin9, Claudio Zanna9, Angela Zubel9, Josep Tabernero7, Keith Flaherty4, David Hyman2
- Dana-Farber Cancer Institute, Boston, MA;
- Memorial Sloan-Kettering Cancer Center,
- Seoul National University Hospital, Seoul, Korea; New York, NY;
- Massachusetts General Hospital Cancer Center, Boston, MA;
- National Cancer Centre Singapore, Singapore;
- The University of Texas MD Anderson Cancer Center, Houston, TX;
- Vall d’Hebron University Hospital, Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain;
- Taipei Medical Hospital University, Taipei, Taiwan;
- Debiopharm International SA, Lausanne, Switzerland